CompletedNot Applicable

High Flow Nasal Cannula Therapy for Early Management of Acute Hypercapnic Cardiogenic Pulmonary Edema in the Emergency Department

France32 participantsStarted 2015-02-01

Plain-language summary

High flow nasal therapy (HFNT) has not been well evaluated for treating hypercapnia The purpose of this study is to determine whether high flow nasal therapy (HFNT) can decrease hypercapnia and improve respiratory distress parameters in Emergency Department patients with acute hypercapnic respiratory failure related to cardiogenic pulmonary edema and to compare its efficacy to that of non invasive ventilation.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: a suspected diagnosis of acute cardiogenic pulmonary edema presenting with any of the following criteria: * dyspnea (orthopnea or a worsening of dyspnea according to NYHA criteria) * respiratory rate \>20 b/min * bilateral crepitant rales at pulmonary auscultation * pulmonary infiltrate on chest X-ray signs of respiratory failure or any of the following clinical, laboratory or radiology signs: * Use of accessory respiratory muscles or paradoxical abdominal movement * Cardiomegaly (cardiothoracic ratio \>0.5) * Hypertensive crisis * PaO2/FiO2 ≤ 300 mmHg breathing O2\> 8L/min or PaO2 ≤ 63mmHg breathing room air hypercapnia (PaCO2\>45 mmHg at arterial blood gas analysis) Exclusion criteria: * acute exacerbation of chronic obstructive pulmonary disease or associated dyspnea from non cardiac origin * Fever (\>38,5°), sepsis or ongoing infection * Contra-indication to NIV

What they're measuring

Change in PaCO2 after a 1-hour treatment session

Timeframe: 1 hour

Trial details

NCT IDNCT03883555

SponsorUniversity Hospital, Montpellier

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2016-09-01